Viridian Therapeutics Stock Investor Sentiment
| VRDN Stock | USD 13.50 0.06 0.44% |
About 54% of Viridian Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Viridian Therapeutics suggests that some traders are interested. Viridian Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Viridian Therapeutics. Many technical investors use Viridian Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Viridian Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Viridian Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of Viridian Therapeutics' Stock prices. Below is the latest headlines and news related to Viridian Therapeutics Stock. Current markets are strongly bullish. About 86% of major world exchanges and indexes are currently up. See today's market update for more information.
There is far too much social signal, news, headlines, and media speculation about Viridian Therapeutics that are available to investors today. This information is accessible both publicly - through Viridian Therapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Viridian-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Viridian Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Viridian Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Viridian Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Viridian Therapeutics alpha.
Viridian Largest EPS Surprises
Earnings surprises can significantly impact Viridian Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-08 | 2024-06-30 | -0.89 | -1.02 | -0.13 | 14 | ||
2022-11-14 | 2022-09-30 | -1.02 | -0.86 | 0.16 | 15 | ||
2022-08-15 | 2022-06-30 | -0.9 | -1.06 | -0.16 | 17 | ||
2023-11-13 | 2023-09-30 | -1.27 | -1.09 | 0.18 | 14 | ||
2021-11-04 | 2021-09-30 | -1.47 | -1.25 | 0.22 | 14 | ||
2025-02-25 | 2024-12-31 | -1.0442 | -0.81 | 0.2342 | 22 |
There is far too much social signal, news, headlines, and media speculation about Viridian Therapeutics that are available to investors today. This information is accessible both publicly - through Viridian Therapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Viridian-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Viridian Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Viridian Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Viridian Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Viridian Therapeutics alpha.
Viridian Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | TANG CAPITAL MANAGEMENT LLC Acquires Significant Stake in Allakos Inc | 02/04/2025 |
2 | Acquisition by Beetham Thomas W. of 474400 shares of Viridian Therapeutics at 13.02 subject to Rule 16b-3 | 02/21/2025 |
3 | Viridian Therapeutics Inc Reports Strong 2024 Progress and Financial Results | 02/27/2025 |
4 | Viridian Therapeutics Full Year 2024 Earnings EPS Beats Expectations, Revenues Lag | 02/28/2025 |
5 | Acquisition by Seth Harmon of 25068 shares of Viridian Therapeutics subject to Rule 16b-3 | 03/03/2025 |
6 | Acquisition by Beetham Thomas W. of 225814 shares of Viridian Therapeutics at 14.41 subject to Rule 16b-3 | 03/04/2025 |
7 | Acquisition by Mahoney Stephen F. of 73428 shares of Viridian Therapeutics subject to Rule 16b-3 | 03/06/2025 |
8 | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 03/10/2025 |
9 | Brokerages Set Viridian Therapeutics, Inc. PT at 35.70 | 03/25/2025 |
10 | Stifel maintains Buy on Viridian Therapeutics, 41 target By Investing.com - Investing.com Canada | 04/04/2025 |
11 | Argenx Moves 4.4 percent Higher Will This Strength Last | 04/15/2025 |
12 | Viridian Therapeutics Given Buy Rating at HC Wainwright | 04/23/2025 |
13 | Insider Trading | 04/25/2025 |
Check out Viridian Therapeutics Hype Analysis, Viridian Therapeutics Correlation and Viridian Therapeutics Performance. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viridian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Viridian Therapeutics is measured differently than its book value, which is the value of Viridian that is recorded on the company's balance sheet. Investors also form their own opinion of Viridian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viridian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viridian Therapeutics' market value can be influenced by many factors that don't directly affect Viridian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viridian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.